ID   A20.IIA
AC   CVCL_0J27
SY   IIA1.6; IIA-1
DR   Wikidata; Q54606430
RX   PubMed=2415625;
RX   PubMed=21949734;
RX   PubMed=22400032;
CC   Cell type: B-cell; CL=CL_0000236.
CC   Breed/subspecies: BALB/cAnN.
DI   NCIt; C134780; Mouse reticulum cell sarcoma
OX   NCBI_TaxID=10090; ! Mus musculus (Mouse)
HI   CVCL_D138 ! A20/2J
SX   Sex unspecified
AG   >15M
CA   Cancer cell line
DT   Created: 10-04-15; Last updated: 05-10-23; Version: 6
//
RX   PubMed=2415625; DOI=10.4049/jimmunol.136.1.348;
RA   Jones B., Tite J.P., Janeway C.A. Jr.;
RT   "Different phenotypic variants of the mouse B cell tumor A20/2J are
RT   selected by antigen- and mitogen-triggered cytotoxicity of
RT   L3T4-positive, I-A-restricted T cell clones.";
RL   J. Immunol. 136:348-356(1986).
//
RX   PubMed=21949734; DOI=10.1371/journal.pone.0024622;
RA   Galand C., Donnou S., Crozet L., Brunet S., Touitou V., Ouakrim H.,
RA   Fridman W.H., Sautes-Fridman C., Fisson S.;
RT   "Th17 cells are involved in the local control of tumor progression in
RT   primary intraocular lymphoma.";
RL   PLoS ONE 6:E24622-E24622(2011).
//
RX   PubMed=22400032; DOI=10.1155/2012/701704;
RA   Donnou S., Galand C., Touitou V., Sautes-Fridman C., Fabry Z.,
RA   Fisson S.;
RT   "Murine models of B-cell lymphomas: promising tools for designing
RT   cancer therapies.";
RL   Adv. Hematol. 2012:701704.1-701704.13(2012).
//